Literature DB >> 22733887

Hydrogen-1 MR spectroscopy for measurement and diagnosis of hepatic steatosis.

Patrick Georgoff1, David Thomasson, Adeline Louie, Estee Fleischman, Lauren Dutcher, Haresh Mani, Shyamasundaran Kottilil, Caryn Morse, Lori Dodd, David Kleiner, Colleen Hadigan.   

Abstract

OBJECTIVE: Hydrogen-1 MR spectroscopy ((1)H-MRS) is gaining acceptance as a noninvasive technique for assessment of hepatic steatosis, and the findings have been found to correlate closely with histopathologic grade. The aims of this study were to validate (1)H-MRS performed with a 3-T MRI system for quantifying hepatic steatosis and to determine threshold values of (1)H-MRS proton density fat fraction corresponding to standard histopathologic grade in patients undergoing diagnostic liver biopsy. SUBJECTS AND METHODS: We conducted a prospective cross-sectional liver MRS study with 52 subjects undergoing diagnostic liver biopsy. The diagnostic accuracy of (1)H-MRS was evaluated with receiver operating characteristic curves.
RESULTS: The diagnostic accuracy of (1)H-MRS for hepatic steatosis was high with an area under the receiver operating characteristic curve of 0.94 (95% CI, 0.88-1.0). Results were similar for three (1)H-MRS measurements obtained at different locations in the liver, for two independent pathologists, and whether fibrosis was present or absent. One third of participants had elevated transaminase concentrations of unknown cause, and (1)H-MRS estimates of steatosis had perfect agreement with histopathologic grade in this group. Calculated (1)H-MRS proton density fat fraction thresholds for histologic grades were less than 17% for grade 0 or trace steatosis, 17-38.6% for grade 1, and greater than 38.6% for grade 2 or higher.
CONCLUSION: Hydrogen-1 MR spectroscopy is an effective, noninvasive technique that can be used to diagnose and quantify hepatic steatosis. Hydrogen-1 MR spectroscopy thresholds corresponded with histopathologic grades and may be useful in the workup of patients with elevated transaminase concentrations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22733887      PMCID: PMC3422734          DOI: 10.2214/AJR.11.7384

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  29 in total

1.  Partial AUC estimation and regression.

Authors:  Lori E Dodd; Margaret S Pepe
Journal:  Biometrics       Date:  2003-09       Impact factor: 2.571

2.  Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population.

Authors:  Lidia S Szczepaniak; Pamela Nurenberg; David Leonard; Jeffrey D Browning; Jason S Reingold; Scott Grundy; Helen H Hobbs; Robert L Dobbins
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-08-31       Impact factor: 4.310

3.  Optimizing the precision in T1 relaxation estimation using limited flip angles.

Authors:  H Z Wang; S J Riederer; J N Lee
Journal:  Magn Reson Med       Date:  1987-11       Impact factor: 4.668

4.  Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis.

Authors:  R Longo; P Pollesello; C Ricci; F Masutti; B J Kvam; L Bercich; L S Crocè; P Grigolato; S Paoletti; B de Bernard
Journal:  J Magn Reson Imaging       Date:  1995 May-Jun       Impact factor: 4.813

5.  Quantification of liver fat using magnetic resonance spectroscopy.

Authors:  C Thomsen; U Becker; K Winkler; P Christoffersen; M Jensen; O Henriksen
Journal:  Magn Reson Imaging       Date:  1994       Impact factor: 2.546

6.  Prospective evaluation of unexplained chronic liver transaminase abnormalities in asymptomatic and symptomatic patients.

Authors:  S Daniel; T Ben-Menachem; G Vasudevan; C K Ma; M Blumenkehl
Journal:  Am J Gastroenterol       Date:  1999-10       Impact factor: 10.864

7.  Noninvasive assessment of hepatic triglyceride content in humans with 13C nuclear magnetic resonance spectroscopy.

Authors:  K F Petersen; A B West; A Reuben; D L Rothman; G I Shulman
Journal:  Hepatology       Date:  1996-07       Impact factor: 17.425

8.  Noninvasive quantitation of human liver steatosis using magnetic resonance and bioassay methods.

Authors:  Gaspard d'Assignies; Martin Ruel; Abdesslem Khiat; Luigi Lepanto; Miguel Chagnon; Claude Kauffmann; An Tang; Louis Gaboury; Yvan Boulanger
Journal:  Eur Radiol       Date:  2009-03-11       Impact factor: 5.315

9.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.

Authors:  R G Knodell; K G Ishak; W C Black; T S Chen; R Craig; N Kaplowitz; T W Kiernan; J Wollman
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

View more
  18 in total

1.  Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.

Authors:  Takara L Stanley; Lindsay T Fourman; Meghan N Feldpausch; Julia Purdy; Isabel Zheng; Chelsea S Pan; Julia Aepfelbacher; Colleen Buckless; Andrew Tsao; Anela Kellogg; Karen Branch; Hang Lee; Chia-Ying Liu; Kathleen E Corey; Raymond T Chung; Martin Torriani; David E Kleiner; Colleen M Hadigan; Steven K Grinspoon
Journal:  Lancet HIV       Date:  2019-10-11       Impact factor: 12.767

2.  Effects of Pitavastatin on Insulin Sensitivity and Liver Fat: A Randomized Clinical Trial.

Authors:  Laurie R Braun; Meghan N Feldpausch; Natalia Czerwonka; Julian Weiss; Karen Branch; Hang Lee; Edgar L Martinez-Salazar; Martin Torriani; Craig A Sponseller; Steven K Grinspoon; Takara L Stanley
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

3.  Clinical usefulness of the mDIXON Quant the method for estimation of the salivary gland fat fraction: comparison with MR spectroscopy.

Authors:  Yoshitaka Kise; Toru Chikui; Yasuo Yamashita; Koji Kobayashi; Kazunori Yoshiura
Journal:  Br J Radiol       Date:  2017-07-14       Impact factor: 3.039

4.  Fibroblast growth factor 21 decreases after liver fat reduction via growth hormone augmentation.

Authors:  Laurie R Braun; Meghan N Feldpausch; Natalia Czerwonka; Martin Torriani; Steven K Grinspoon; Takara L Stanley
Journal:  Growth Horm IGF Res       Date:  2017-10-07       Impact factor: 2.372

5.  Free-breathing quantification of hepatic fat in healthy children and children with nonalcoholic fatty liver disease using a multi-echo 3-D stack-of-radial MRI technique.

Authors:  Tess Armstrong; Karrie V Ly; Smruthi Murthy; Shahnaz Ghahremani; Grace Hyun J Kim; Kara L Calkins; Holden H Wu
Journal:  Pediatr Radiol       Date:  2018-05-04

6.  Magnetic resonance spectroscopy to assess hepatic steatosis in patients with lipodystrophy.

Authors:  Canan Altay; Mustafa Seçil; Süleyman Cem Adıyaman; Başak Özgen Saydam; Tevfik Demir; Gülçin Akıncı; Ilgın Yıldırım Simsir; Erdal Eren; Ela Temeloğlu Keskin; Leyla Demir; Hüseyin Onay; Haluk Topaloğlu; Banu Sarer Yürekli; Nilüfer Özdemir Kutbay; Ramazan Gen; Barış Akıncı
Journal:  Turk J Gastroenterol       Date:  2020-08       Impact factor: 1.852

7.  Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection.

Authors:  Lindsay Matthews; David E Kleiner; Cheryl Chairez; Maryellen McManus; Mary Jane Nettles; Kira Zemanick; Caryn Gee Morse; Debra Benator; Joseph A Kovacs; Colleen Hadigan
Journal:  AIDS Res Hum Retroviruses       Date:  2015-08-24       Impact factor: 2.205

8.  Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.

Authors:  Takara L Stanley; Meghan N Feldpausch; Jinhee Oh; Karen L Branch; Hang Lee; Martin Torriani; Steven K Grinspoon
Journal:  JAMA       Date:  2014 Jul 23-30       Impact factor: 56.272

Review 9.  4Ps medicine of the fatty liver: the research model of predictive, preventive, personalized and participatory medicine-recommendations for facing obesity, fatty liver and fibrosis epidemics.

Authors:  Francesca Maria Trovato; Daniela Catalano; Giuseppe Musumeci; Guglielmo M Trovato
Journal:  EPMA J       Date:  2014-12-07       Impact factor: 6.543

10.  Noninvasive diagnosis of pediatric nonalcoholic fatty liver disease.

Authors:  Hye Ran Yang
Journal:  Korean J Pediatr       Date:  2013-02-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.